Fluorene compound and pharmaceutical use thereof

Abstract

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

1 - 35 . (canceled) 
     
     
         36 . The compound which is represented by the following formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof: 
       
         
           
           
               
               
           
         
       
     
     
         37 . The compound which is represented by the following formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof: 
       
         
           
           
               
               
           
         
       
     
     
         38 . A pharmaceutical composition comprising the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier. 
     
     
         39 . A method of inhibiting PDHK in a mammal, comprising administering a pharmaceutically effective amount of the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof to the mammal. 
     
     
         40 . A method of inhibiting PDHK2 in a mammal, comprising administering a pharmaceutically effective amount of the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof to the mammal. 
     
     
         41 . A method of decreasing the blood glucose level in a mammal, comprising administering a pharmaceutically effective amount of the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof to the mammal. 
     
     
         42 . A method of decreasing lactate level in a mammal, comprising administering a pharmaceutically effective amount of the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof to the mammal. 
     
     
         43 . A method for the treatment or prophylaxis of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer in mammal, comprising administering a pharmaceutically effective amount of the compound of any one of  claims 36  to  37 , or a pharmaceutically acceptable salt thereof, or a solvate thereof to the mammal.